Intrauterine Insemination (IUI) Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (IUI Catheters v/s IUI Media/Sperm Wash), By End User (Hospitals, IVF Centers & Clinics, Others), and By Region 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 445.97 Million
CAGR (2026-2031)	6.91%
Fastest Growing Segment	IUI Catheters
Largest Market	North America
Market Size (2031)	USD 665.91 Million

Market Overview

The Global Intrauterine Insemination (IUI) Devices Market will grow from USD 445.97 Million in 2025 to USD 665.91 Million by 2031 at a 6.91% CAGR. Intrauterine Insemination (IUI) devices comprise specialized medical instruments, such as insemination catheters and sperm processing kits, utilized to deposit prepared sperm directly into the uterus to facilitate natural fertilization. The market is primarily driven by the escalating global prevalence of infertility and a growing patient preference for this less invasive, cost-efficient alternative to in vitro fertilization. Additionally, expanding insurance coverage and favorable reimbursement policies in developed nations are significantly increasing the accessibility of these primary fertility interventions.

Despite these positive factors, the market faces challenges regarding the comparatively lower success rates per cycle of IUI versus more advanced assisted reproductive technologies, which can deter adoption among patients seeking rapid clinical outcomes. This demand remains substantial; according to the European Society of Human Reproduction and Embryology, in 2025, clinics across Europe reported performing over 168,000 intrauterine insemination treatment cycles during the 2022 surveillance period.

Key Market Drivers

The rising global incidence of male and female infertility acts as a fundamental driver for the Global Intrauterine Insemination (IUI) Devices Market, creating sustained demand for specialized catheters and sperm preparation media. As physiological barriers to conception become more prevalent, clinical reliance on assisted reproductive technologies has intensified to address these reproductive health challenges. According to Forbes, December 2025, in the 'WHO Releases Infertility Guidelines As Global Fertility Rates Fall' article, approximately 13.4% of U.S. women aged 15 to 49 grapple with infertility issues, necessitating medical interventions like IUI. This widespread prevalence ensures a continuous patient influx for fertility clinics, directly stimulating the procurement of insemination devices designed to bypass cervical barriers and enhance fertilization probabilities.

Simultaneously, the shift toward delayed parenthood and advanced maternal age significantly influences market expansion, as biological fertility declines prompt earlier clinical engagement. Women are increasingly postponing childbirth for professional or personal reasons, leading to a demographic landscape where natural conception becomes statistically more difficult. According to the Human Fertilisation and Embryology Authority, September 2024, in the 'Fertility Trends & Figures Report', the average age of patients starting IVF was over 35 years old for the first time, highlighting the aging profile of fertility patients. This demographic trend amplifies the need for accessible first-line treatments before progressing to more invasive options. The economic accessibility of these devices further supports this adoption; according to Kofinas Fertility Group, in 2025, the typical cost of an IUI cycle ranges from a few hundred dollars to approximately $2,000, making it a financially viable preliminary step for many couples.

Download Free Sample Report

Key Market Challenges

The Global Intrauterine Insemination (IUI) Devices Market faces a substantial hurdle regarding the comparatively low clinical success rates of IUI procedures when contrasted with advanced assisted reproductive technologies (ART) like in vitro fertilization (IVF). This efficacy gap creates a significant reluctance among patients and healthcare providers to persist with multiple insemination cycles. As the desire for rapid successful outcomes often outweighs the initial cost advantages of IUI, there is a marked trend of patients accelerating their transition to high-efficacy ART treatments. This shift shortens the window of opportunity for IUI device utilization, thereby capping the volume of catheters and sperm processing kits consumed per patient.

Consequently, the market struggles to maintain growth momentum as the "time-to-pregnancy" metric becomes a priority for older patient demographics who might otherwise be candidates for IUI. This disparity in outcomes is well-documented and influences clinical pathways. According to the European Society of Human Reproduction and Embryology, in 2024, surveillance data reported that clinical pregnancy rates for IVF procedures reached approximately 33.5% per embryo transfer, presenting a compelling performance advantage over the historically lower single-cycle success rates of insemination. This statistical reality drives demand toward ART alternatives, directly constraining the expansion of the IUI devices sector.

Key Market Trends

The adoption of microfluidic sperm sorting technologies is fundamentally reshaping the preparation phase of intrauterine insemination by replacing traditional centrifugation methods that often induce oxidative stress and DNA fragmentation in sperm cells. These microfluidic chips mimic the natural physiological barriers of the female reproductive tract, allowing only the most motile and genomically competent sperm to pass through a membrane for collection. This technological shift is critical for improving clinical outcomes in IUI procedures where sample quality is a primary determinant of success, particularly given the reliance on the sperm's natural ability to fertilize. Validating this efficacy, according to the National Institutes of Health, July 2025, in the 'Clinical validation and experiences of the microfluidics sperm selection device ZyMōt™ for standard IVF' study, the use of microfluidic sorting resulted in a significantly higher purity of samples, achieving a fraction of progressive motile sperm of 97.2% compared to only 83.0% with density gradient centrifugation.

Simultaneously, the proliferation of home-based fertility monitoring solutions is decentralizing cycle management, allowing patients to precisely track ovulation windows and hormone levels outside the clinical setting to optimize insemination timing. This trend reduces the logistical burden of frequent clinic visits for follicular monitoring and empowers patients with real-time physiological data to coordinate IUI procedures more effectively. The scale of this adoption is evident in the rapid accumulation of patient health metrics; according to Indian Retailer, December 2025, in the '{Funding Alert} Inito Bags $29 Mn Series B Round to Scale AI-Based At-Home Health Testing' article, the Inito fertility monitor platform has already analyzed more than 30 million hormone data points, demonstrating the massive integration of remote diagnostics into modern fertility treatment pathways.

Segmental Insights

The IUI Catheters segment is the fastest-growing component of the Global Intrauterine Insemination Devices Market, driven primarily by the recurring demand for these single-use consumables. Unlike capital equipment, catheters require frequent replenishment as rising infertility rates necessitate higher procedure volumes globally. Manufacturers are focusing on design improvements, offering catheters with optimal flexibility to ensure precise sperm placement and patient comfort. Furthermore, rigorous compliance with safety standards from regulatory bodies like the FDA enhances clinical confidence in these products. This combination of high consumption volume and functional advancement solidifies the segment's rapid expansion.

Regional Insights

North America maintains a leading position in the Global Intrauterine Insemination (IUI) Devices Market, driven by the rising prevalence of infertility and an established healthcare infrastructure. The region benefits from high patient awareness regarding fertility treatments and the strong presence of key medical device manufacturers. Additionally, stringent product safety standards enforced by the U.S. Food and Drug Administration ensure high clinical quality, fostering provider confidence. Favorable reimbursement scenarios and supportive guidelines from organizations like the American Society for Reproductive Medicine further catalyze market activity, securing the region's dominance.

Recent Developments

• In December 2024, the private equity firm Astorg announced the completion of its acquisition of Cook Medical's Reproductive Health business, alongside the take-private of Hamilton Thorne. The transaction merges these entities to establish a new global leader in assisted reproductive technology (ART) and in vitro fertilization (IVF) devices. The acquired business from Cook Medical contributes a significant portfolio of ART consumables and equipment, including ovum aspiration needles and intrauterine insemination catheters. This strategic consolidation aims to offer fertility clinics and laboratories a comprehensive range of high-quality products and improve access to fertility treatments worldwide.
• In June 2024, CooperSurgical announced the acquisition of ZyMōt Fertility, a company specializing in advanced sperm separation technology. This strategic addition enhances the acquiring company's portfolio of assisted reproductive technology (ART) products by integrating a patented device that separates motile sperm without the need for centrifugation. The technology is designed to improve sperm quality for procedures such as intrauterine insemination (IUI) and in vitro fertilization (IVF) by reducing DNA fragmentation. This acquisition underscores the industry's shift towards minimizing sperm damage during processing to potentially increase pregnancy success rates in fertility treatments.
• In March 2024, Femasys Inc. announced positive topline data from a pivotal clinical trial evaluating its novel intratubal insemination device. The study highlighted the device's efficacy in treating severe male factor infertility, demonstrating a pregnancy rate significantly higher than historical rates associated with standard intrauterine insemination (IUI). Designed to deliver sperm directly into the fallopian tube, the device offers a less invasive alternative to in vitro fertilization (IVF) while serving as a potential upgrade to traditional IUI procedures. Following these results, the company successfully completed the first commercial procedure using this FDA-cleared technology.
• In January 2024, PherDal Fertility Science commenced pre-orders for its sterile at-home insemination kit following FDA Class II clearance. The product is marketed as the first sterile, over-the-counter intravaginal insemination device designed to mimic the sterile environment of a clinical setting. The kit includes a patented syringe intended to bypass bacterial interference by delivering sperm directly to the cervical opening. This launch represents a significant development in the market, bridging the gap between natural conception and clinical procedures like intrauterine insemination (IUI) by providing a regulated, accessible option for home use.

Key Market Players

• Kitazato Corporation
• Gynotec B.V.
• Rocket Medical plc.
• CooperSurgical, Inc.
• Cook Group Inc.
• Prince Medical SAS
• Surgimedik Healthcare India Private Limited
• MedGyn Products, Inc.
• MediTech Devices Pvt. Ltd.
• Biorad Medisys Pvt. Ltd.

By Product	By End User	By Region
IUI Catheters v/s IUI Media/Sperm Wash	Hospitals IVF Centers & Clinics Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Intrauterine Insemination (IUI) Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Intrauterine Insemination (IUI) Devices Market, By Product:

• IUI Catheters v/s IUI Media/Sperm Wash

• Intrauterine Insemination (IUI) Devices Market, By End User:

• Hospitals
• IVF Centers & Clinics
• Others

• Intrauterine Insemination (IUI) Devices Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE